These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 8129387)

  • 1. [Phase II study of CGS16949A, a new aromatase inhibitor--a dose finding study].
    Tominaga T; Abe O; Asaishi K; Abe R; Enomoto K; Kajiwara T; Yoshida M; Wada T; Nomura Y
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):465-75. PubMed ID: 8129387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)].
    Wada T; Nomura Y; Oohashi Y; Abe O; Koyama H; Takashima S
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):485-93. PubMed ID: 8129389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase I study of CGS16949A--a new aromatase inhibitor. Cooperative Study Group for CGS16949A].
    Nomura Y; Abe O; Tominaga T; Tashiro H; Hisamatsu K; Enomoto K; Fujiwara K; Imoto S; Ando J; Hayashi K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):189-97. PubMed ID: 8311489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of CGS16949A in advanced or recurrent breast cancer--a multi-institutional late phase II clinical trial].
    Aoyama H; Asaishi K; Abe R; Kajiwara T; Enomoto K; Yoshida M; Ohasi Y; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):477-84. PubMed ID: 8129388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
    Tominaga T; Suzuki T
    Anticancer Res; 2003; 23(4):3533-42. PubMed ID: 12926103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer].
    Kanzaki M; Nakaya Y; Kojima K; Toda H; Tobayama S; Machida H; Ohba M
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):959-65. PubMed ID: 10396324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
    Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
    Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
    Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study].
    Aoyama H; Tominaga T; Abe O
    Gan To Kagaku Ryoho; 1998 May; 25(6):853-65. PubMed ID: 9617324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A combined effect of fadrozole and tamoxifen in postmenopausal patients with recurrent breast cancer: a preliminary report: Japanese Cooperative Study Group of Fadrozole and Tamoxifen].
    Tominaga T; Kimura M; Toge T; Takashima S; Nomura Y; Ohashi Y
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1709-18. PubMed ID: 11057322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer].
    Asaishi K; Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):91-9. PubMed ID: 8422190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
    Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group].
    Fukuda M; Watanabe H; Suda T; Shimizu S
    Gan To Kagaku Ryoho; 1999 Dec; 26(14):2201-8. PubMed ID: 10635305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
    Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with breast cancer--multi-center cooperative study--Cooperative Study Group of 590-S in Breast Cancer].
    Taguchi T; Terasawa T
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):467-71. PubMed ID: 3813575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
    Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.